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Purpose: Although a population’s senescence rate is classically measured as the increase in mortality rate
with age on a logarithmic scale, it may be more accurately measured as the increase on a linear scale.
Patients on dialysis, who suffer from accelerated senescence, exhibit a smaller increase in their mortality
rate on a logarithmic scale, but a larger increase on a linear scale than patients with a functioning kidney
transplant. However, this comparison may be biased by population heterogeneity.
Methods: Follow-up data on 323,308 patients on dialysis and 91,679 patients with a functioning kidney
transplant were derived from the ERA-EDTA Registry. We measured the increases in their mortality rates
using Gompertz frailty models that allow individual variation in this increase.
Results: According to these models, the senescence rate measured as the increase in mortality rate on a
logarithmic scale was smaller in patients on dialysis, while the senescence rate measured as the increase
on a linear scale was larger in patients on dialysis than patients with a functioning kidney transplant.
Conclusions: Also when accounting for population heterogeneity, a population’s senescence rate is more
accurately measured as the increase in mortality rate on a linear scale than a logarithmic scale.
 2016 Elsevier Inc. All rights reserved.hD, Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, Postal
lands. Tel.: þ31-71-5266640; fax: þ31-71-5266912.
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Senescence is constituted by a complex of biological mecha-
nisms that lead to an increase in vulnerability to death from
adolescence onward. A population’s senescence rate can conse-
quently be measured as an increase in mortality rate with age
[1e3]. Classically, increases in mortality rates are measured on a
logarithmic scale, which can be done using the Gompertz model
[1e3]. However, it has been argued that the increase in mortality
rate on a logarithmic scale is an inaccurate measure of a pop-
ulation’s senescence rate [4]. Instead, it has been proposed that the
senescence rate should be measured as the increase in mortality
rate on a linear scale, which can also be determined using the
Gompertz model [5]. This proposition has been empirically tested
in patients with end-stage renal disease on dialysis and with a
functioning kidney transplant [6]. Patients on dialysis are generally
acknowledged to suffer both clinically and biologically from accel-
erated senescence. They exhibit higher prevalences and more rapid
progression of various age-related disorders as compared with the
general population. After kidney transplantation, these phenomena
of accelerated senescence improve [6e9]. When measured as the
increases in their mortality rates on a logarithmic scale, patients on
dialysis have a lower senescence rate than patients with a func-
tioning transplant. By contrast, when measured as the increases in
their mortality rates on a linear scale, patients on dialysis have a
higher senescence rate than patients with a functioning transplant
[6]. These ﬁndings support the proposition that a senescence rate
measured as the increase in mortality rate on a linear scale corre-
spondsmore accurately with clinical and biological knowledge than
a senescence rate measured as the increase in mortality rate on a
logarithmic scale.
Previous comparisons of both methods may have been biased
because they have not accounted for population heterogeneity.
Most populations are heterogeneous as they consist of individuals
with different levels of frailty [10e12]. Distinctive from the clinical
diagnosis of frailty, all individuals can be attributed a level of frailty
in this statisticaleepidemiological sense. At any age, individuals
with higher levels of frailty suffer from an elevated mortality rate as
compared with less frail individuals. In patients with end-stage
renal disease, differences in frailty may result from varieties in
primary renal disease, treatmentmodality, quality of care, ethnicity,
and country [13e17]. Heterogeneity among patients on dialysis is
likely greater than among patients with a functioning transplant
because the more healthy patients are considered eligible for
transplantation [13e15]. Subpopulations with different levels of
frailty may display age-dependent increases in mortality rates that
are different as well as different from the increase observed in the
population as a whole [10e12]. Consequently, a senescence rate
measured as the increase in mortality rate with age in a population
as a whole may not correctly represent the senescence rates of the
different subpopulations.
Extensions of models like the Gompertz model have been
developed to account for population heterogeneity [10e12], but
these models have not yet been used for comparing both methods
to measure senescence rates. These models contain a frailty
parameter that allows individual variation in the age-dependent
increase in mortality rate. Here, we use such Gompertz frailty
models to measure the senescence rates of patients with end-stage
renal disease on dialysis and with a functioning kidney transplant
while accounting for population heterogeneity. Now uncovering
the possible bias due to population heterogeneity, we aim to
compare the senescence rates measured as the increases in their
mortality rates on a logarithmic scale, according to the classical
method, and measured as the increases in their mortality rates on a
linear scale, according to the alternative method.Methods
Study population
This study included data from 27 national and regional registries
(see Appendix A) participating in the Registry of the European Renal
AssociationeEuropean Dialysis and Transplant Association. These
registries record the treatment and survival history of European
patients receiving renal replacement therapy, either dialysis or
kidney transplantation [15]. Patients were included if renal
replacement therapy was started in or after 1985; follow-up ended
on January 1, 2013. At baseline, the country or region of origin, birth
date, sex, and primary renal diseasewere registered for each patient.
Countries or regions of origin were grouped into four categories:
Western Europe, Northern Europe, Southeastern Europe, and
SouthwesternEurope (seeAppendixA). Primary renal diseaseswere
also grouped into four categories: glomerular diseases including
glomerulonephritis and glomerulosclerosis, pyelonephritis,
vascular diseases including renal diseases due to diabetes mellitus,
hypertension, and vascular disease and other or unknown diseases.
Follow-up and crude mortality rates
During follow-up, the dates and modalities of renal replacement
therapy and the date of death were collected for each patient from
the age of 20 years onward. For patients on dialysis, follow-up
started 6 months after initiation of dialysis, excluding early mor-
tality related to dialysis treatment or preceding transplantation,
and lasted until death, transplantation, recovery of renal function,
loss to follow-up, or January 1, 2013. The type of dialysis was
categorized as hemodialysis or peritoneal dialysis. For patients with
a functioning transplant, follow-up started 6 months after trans-
plantation, excluding early mortality related to surgery or preced-
ing dialysis treatment, and lasted until death, transfer to dialysis
due to transplant failure, loss to follow-up, or January 1, 2013. Each
transplantation was categorized according to the type of donor,
being a deceased donor, living donor, or unknown donor.
Crude age-speciﬁc mortality rates were calculated from the
follow-updata of the individual patientswithout using theGompertz
model by dividing the number of deaths by the number of person-
years of follow-up per 5-year age group. Conﬁdence intervals of the
mortality rates were calculated using Byar’s formula [18].
Mortality rates determined by the Gompertz models
The Gompertz model is described by m(t) ¼ a egt, where m(t) is
the mortality rate at age t and a and g the model’s parameters. We
used two Gompertz models that accounted for population hetero-
geneity. Both models were adjusted for covariates that affect the
mortality rates, including the patient’s sex, country of origin, pri-
mary renal disease, type of dialysis, and type of kidney donor. In
addition, each model contained a random frailty parameter z that
allowed further individual variation in the mortality rates through
variation in either of the Gompertz model’s parameters a and g.
Variation in a multiplies mortality rates at all ages by an age-
independent factor; variation in g multiplies mortality rates by a
factor that increases with age. The Gompertz frailty models were
ﬁtted to the follow-up data by numerically integrating the frailty
parameter z and numerically maximizing the log-likelihood with
respect to a, g, and z, as explained in more detail in Appendix A.
Senescence rates determined by the Gompertz models
We determined the senescence rates of the patients using the
two Gompertz frailtymodels. The senescence rates measured as the
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to the classical method, are determined by the derivative functions
of the logarithmically transformed models. The senescence rates
measured as the increases in their mortality rates on a linear scale,
according to the alternative method, are determined by the deriv-
ative function of the model without logarithmic transformation.
The derivative functions of the Gompertz frailty models are given in
Appendix A.
The Gompertz frailtymodels were ﬁtted, andmortality rates and
senescence rates were measured by these models using R, version
3.0 (R Foundation for Statistical Computing, Vienna, Austria).Results
Table 1 describes the characteristics of the study population.
Because patients could undergo both dialysis treatment and kidney
transplantation, 60,817 patients (17.2%) contributed 575,858
person-years of follow-up (34.6%) to both treatment groups. The
maximum number of a patient’s treatments of dialysis and trans-
plantation was 14 years.
Figure 1 shows the age-speciﬁc mortality rates of patients on
dialysis and patients with a functioning transplant. The crude
mortality rates calculated without using the Gompertz model are
indicated in gray. At all ages, mortality rates were higher in patients
on dialysis than patients with a functioning transplant. On a linear
scale (Fig. 1A and 1B), the mortality rates increased exponentially
but leveled in patients on dialysis and declined in patients with a
functioning transplant after the age of 85e90 years, whereas the
conﬁdence intervals widened after these ages due to decreasing
numbers of patients. On a logarithmic scale (Fig. 1C and 1D), the
exponential increases in the mortality rates conformed to a linear
increase and their leveling and decline were discernible as a devi-
ation from the linear increase.
We ﬁtted two Gompertz frailty models to the follow-up data of
patients on dialysis and patients with a functioning transplant: one
with a frailty parameter z allowing individual variation in the
model’s parameter a and one with a frailty parameter z allowingTable 1
Characteristics of the study population of patients with end-stage renal disease
Characteristic All patients
At baseline
Patients, n 354,170
Males, n (%) 217,864 (61.5)
Age at ﬁrst treatment, median (IQR), y 64.2 (51.2e74.1)
Region of origin, n (%)
Western Europe 136,873 (38.6)
Northern Europe 45,307 (12.8)
Southeastern Europe 42,426 (12.0)
Southwestern Europe 129,564 (36.6)
Primary renal disease, n (%)
Glomerular diseases 52,957 (15.0)
Pyelonephritis 26,041 (7.4)
Vascular diseases 132,381 (37.4)
Other 142,791 (40.3)
Follow-up
Total follow-up, person-years 1,665,939
Follow-up per patient, median (IQR) person-years 3.4 (1.7e6.2)
Dialysis modality, person-years (%)
Hemodialysis d
Peritoneal dialysis d
Transplant source, person-years (%)
Deceased donor d
Living donor d
Unknown d
Deaths, n (%) 171,464 (48.4)
Age at death, median (IQR) years 73.4 (64.7e79.9)individual variation in the model’s parameter g. The obtained
values for the models’ parameters are given in Table 2.
In Figure 1, the mortality rates of patients on dialysis and
patients with a functioning transplant determined by the Gompertz
frailty models are indicated in black. According to both models, the
mortality rates were at all ages higher in patients on dialysis than
patients with a functioning transplant. The mortality rates deviated
from an exponential increase at the highest ages in both patient
groups, deviating more according to the Gompertz frailty model
with variation in g than the Gompertz frailty model with variation
in a. The mortality rates determined by the Gompertz frailty model
with variation in a corresponded better with the crude mortality
rates than those determined by the Gompertz frailty model with
variation in g in patients on dialysis. At the highest ages, the mor-
tality rates as determined by the Gompertz frailty model with
variation in g corresponded better, but not well, with the leveling or
declining crude mortality rates in both patients groups.
Figure 2 shows the age-speciﬁc senescence rates of patients on
dialysis and patients with a functioning transplant. According to the
classical method, the senescence rates were measured as the in-
creases in their mortality rates on a logarithmic scale using the
derivative functions of the logarithmically transformed Gompertz
frailty models (Fig. 2A and 2B). These senescence rates were at all
ages lower in patients on dialysis than patients with a functioning
transplant according to both models. The difference in senescence
rate between both patient groups was larger according to the
Gompertz frailty model with variation in a. The senescence rates
were nearly constant according to the Gompertz frailty model with
variation in a (Fig. 2A) but decreased in both patient groups ac-
cording to the Gompertz frailty model with variation in g (Fig. 2B).
According to the alternative method, the senescence rates of
patients on dialysis and patients with a functioning transplant were
measured as the increases in their mortality rates on a linear scale
using the derivative functions of the Gompertz frailty models
without logarithmic transformation (Fig. 2C and 2D). According to
both models, these senescence rates were at all ages higher in
patients on dialysis than patients with a functioning transplant. The
senescence rates increased nearly exponentially according to thePatients on dialysis Patients with a functioning kidney transplant
323,308 91,679
198,611 (61.4) 57,433 (62.6)
65.8 (53.6e74.9) 49.8 (38.4e59.6)
125,873 (38.9) 37,515 (40.9)
38,910 (12.0) 15,999 (17.5)
41,373 (12.8) 4084 (4.5)
117,152 (36.2) 34,081 (37.2)
45,076 (13.9) 23,753 (25.9)
23,239 (7.2) 8251 (9.0)
126,656 (39.2) 19,296 (21.0)
128,337 (39.7) 40,379 (44.0)
1,049,987 615,952
2.5 (1.3e4.4) 5.4 (2.7e9.4)
901,710 (85.9) d
148,278 (14.1) d
d 471,799 (76.6)
d 115,512 (18.8)
d 28,641 (4.6)
158,736 (49.1) 12,728 (13.9)
74.1 (65.7e80.3) 64.2 (55.7e71.0)
A B
C D
Fig. 1. Mortality rates of patients with end-stage renal disease. Age-speciﬁc mortality rates of patients on dialysis and patients with a functioning kidney transplant as measured by
the Gompertz frailty model with variation in a (A and C) and the Gompertz frailty model with variation in g (B and D) are indicated in black. Their crude mortality rates with 95%
conﬁdence intervals calculated without using the Gompertz model are indicated in gray. Both are given on a linear (A and B) and on a logarithmic scale (C and D). The dotted lines
indicate linear increases on the logarithmic scale (C and D). Py ¼ person-years.
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exponential increase and leveled at the highest ages in both patient
groups according to the Gompertz frailty model with variation in g.
These senescence rates reached higher levels according to the
Gompertz frailty model with variation in a than the Gompertz
frailty model with variation in g.
To visualize to what extent the increases in the mortality rates
and senescence rates were allowed to vary by the Gompertz frailty
models through variation in one of each model’s parameters, the
mortality rates and senescence rates for subpopulations with
different levels of frailty are shown in Appendix B. The range
covered by these subpopulations includes 95% of the patients.
According to the Gompertz frailty model with variation in a, a
ranged from 0.45 to 0.56 in patients on dialysis and from 0.05 to
0.07 in patients with a functioning transplant. According to the
Gompertz frailty model with variation in g, g ranged from 4.59 to
5.49 in patients on dialysis and from 5.24 to 6.83 in patients with a
functioning transplant. These parameters’ values are given multi-
plied by 100 for readability. The variation in the age patterns wassmaller according to the Gompertz frailty model with variation in a
as compared with the Gompertz frailty model with variation in g.
When repeating the analyses after excluding follow-up from the
age of 85 years onward, similar results were obtained (data not
shown).
Discussion
This study aims to compare the senescence rates of patients with
end-stage renal disease on dialysis and with a functioning kidney
transplant measured as the increases in their mortality rates on a
logarithmic scale, according to the classical method, and measured
as the increases in their mortality rates on a linear scale, according
to an alternative method. Measured on a logarithmic scale, patients
on dialysis had a lower senescence rate than patients with a func-
tioning transplant. By contrast, measured on a linear scale, patients
on dialysis had a higher senescence rate than patients with a
functioning transplant. The alternative method, rather than the
classical method, corresponds with the general knowledge that
Table 2
Parameters of the Gompertz frailty models for patients with end-stage renal disease
Parameter Patients on dialysis Patients with a functioning
kidney transplant
Gompertz frailty model
with variation in a
a 0.50 (0.49e0.52) 0.06 (0.05e0.07)
g 4.87 (4.84e4.91) 6.23 (6.10e6.36)
s 5.27 (4.51e6.15) 6.94 (3.95e12.20)
Gompertz frailty model
with variation in g
a 0.39 (0.38e0.40) 0.07 (0.06e0.07)
g 5.02 (5.01e5.04) 5.98 (5.91e6.05)
s 4.56 (4.42e4.71) 6.77 (5.94e7.73)
The values of the parameters of the Gompertz frailty models are given with 95%
conﬁdence intervals and multiplied by 100 for readability. The Gompertz model is
described by parameter a, which determines the minimal mortality rate at the
youngest age, and by parameter g, which determines the subsequent increase in
mortality rate with age. The Gompertz frailty models have an additional frailty
parameter z that allows variation in either parameter a or g and has a normal dis-
tribution with a mean of 0 and a standard deviation of s.
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accelerated senescence, whereas their senescence decelerates after
transplantation [6e9].
Both methods to measure senescence rates have previously
been compared in a smaller group of patients on dialysis and with a
functioning kidney transplant, which is part of the population
included in this study [6]. The results of this study are similar to the
previous. As its novel contribution, this study extends the previous
comparisons by using Gompertz frailty models that uncover
possible bias due to population heterogeneity in two manners.
Observed population heterogeneity was accounted for by adjusting
the Gompertz model for known differences between sub-
populations that affect the mortality rate, including the patient’s
sex, country of origin, primary renal disease, type of dialysis, and
type of kidney donor. In addition, unobserved population hetero-
geneity was accounted for by adding a frailty parameter to the
Gompertz model that allowed further individual variation in the
increases in their mortality rates with age.
Moreover, we found that the senescence rates decreased with
age according to the classical method, whereas they increased with
age according to the alternative method. Increasing, rather than
decreasing, senescence rates correspond with the general knowl-
edge that older individuals exhibit higher prevalences and more
rapid progression of various age-related disorders and a higher
mortality rate as compared with younger individuals, also among
patients with end-stage renal disease [1e3,5e9,13e16]. Together,
these results reinforce the proposition that a population’s senes-
cence rate is more accurately measured as the increase in mortality
rate on a linear scale than on a logarithmic scale, also when ac-
counting for population heterogeneity.
We used one Gompertz frailty model with individual variation
in the Gompertz model’s parameter a and another one with indi-
vidual variation in the Gompertz model’s parameter g. When a
varies, mortality rates at all ages are multiplied by an age-
independent factor; the effect of variation in a is similar at all
ages. When g varies, mortality rates are multiplied by a factor that
increases with age; variation in g has a greater effect at higher ages.
In line with this, we found that the increases in the mortality rates
with age varied less according to the Gompertz frailty model with
variation in a than the Gompertz frailty model with variation in g
(Appendix B).
Mostly, the Gompertz frailty model with variation in a is used
when the effects of population heterogeneity on the increases in
mortality rates with age are studied [10e12]. This model explains
leveling and declining mortality rates in several populations[19e21]. Gompertz frailty models with variation in g have only
recently been used and have been shown to explain leveling and
declining mortality rates but have only rarely been applied to
mortality data of human populations [22e25]. We found that the
Gompertz frailty model with variation in g allowed the mortality
rates to deviate more from an exponential increase and explained
the leveling mortality rates better than the Gompertz frailty model
with variation in a.
A population’s senescence rate can also be derived from the
increase in mortality rate on a linear scale without using the
Gompertz model [26]. Such a method enables the discovery of de-
viations from the exponential increases in mortality rate with age
that are described by the Gompertz model. Leveling and declining
mortality rates have been observed in populations at high ages
[19,27], among which patients with end-stage renal disease [26]. It
is presumed that such deviations may be effects of population
heterogeneity, brought about by the joint study of subpopulations
that have different levels of frailty [3,10e12]. When these sub-
populations are studied separately, mortality rates increase expo-
nentially up to the highest ages [28]. Consistent with this
presumption, the Gompertz frailty models in this study that
uncover population heterogeneity yielded leveling mortality rates.
However, the Gompertz frailty models could not explain the
observation of declining mortality rates. Other explanations than
population heterogeneity can cause mortality rates to level and
decline but are difﬁcult to detect [22]. These other explanationsmay
include the selection of relatively healthy patients for treatment at
high age, the deceleration or cessation of senescence in individuals
[22,27,29], and randomness or inaccuracy of the data [28].
More than estimating the senescence rates of patients on dial-
ysis and patients with a functioning kidney transplant, of whom the
former are generally known to age faster than the latter, this study
reinforces the proposition that the alternative method to measure
senescence rates is more accurate than the classical method. It
shows that the conclusions based on both methods may even be
opposite. It underscores, in general, the importance of verifying the
validity of a method to measure the senescence rate of any
population.
The classical method and the alternative method to measure
senescence rates, whichwere compared in this study, represent two
different deﬁnitions of the senescence rate. According to the clas-
sical method, the senescence rate is the relative increase in mor-
tality rate with age, whereas according to the alternative method, it
is the absolute increase in mortality rate. We have explained else-
where how both deﬁnitions mathematically relate to each other
and why they consequently may lead to opposite results [30].
It is essential for research on senescence to measure and
compare senescence rates of populations. In humans, this is done to
explore differences in senescence across time periods, environ-
ments, and ethnicities to reveal the inﬂuences on senescence of
evolutionary, environmental, and genetic characteristics and to
assess the effects on senescence of genetic and environmental risk
factors and interventions [30]. The classical method is extensively
used to measure senescence rates in research, but a reassessment
using other methods, such as the alternative method studied here,
may radically change previous conclusions. In the absence of
agreement on the measurement of the senescence rate, one may
resort to measuring an age-independent risk of mortality. However,
a risk of mortality by itself does not reﬂect senescence; only the
increase in this risk with age can be used to measure senescence
[30]. One can choose to refrain from using models like the Gom-
pertz model and to measure senescence rates nonparametrically as
has been shown elsewhere [26]. Finally, one can measure a decline
in health with age, which is a manifestation of senescence similar to
the increase in vulnerability to death. Ideally, the narrow focus of
A B
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Fig. 2. Senescence rates of patients with end-stage renal disease measured by the Gompertz frailty models. Age-speciﬁc senescence rates of patients on dialysis and patients with a
functioning kidney transplant measured by the Gompertz frailty model with variation in a (A and C) and the Gompertz frailty model with variation in g (B and D). The senescence
rates were measured as the increases in their mortality rates on a logarithmic scale, according to the classical method (A and B), and, according to the alternative method, measured
as the increases in their mortality rates on a linear scale (C and D). Py ¼ person-years.
J.J.E. Koopman et al. / Annals of Epidemiology 26 (2016) 773e779778research on senescence using the classical method is com-
plemented by a comparison with the use of these other methods.
In conclusion, a population’s senescence rate is more accurately
measured as the increase in mortality rate on a linear scale than on
a logarithmic scale, also when using Gompertz frailty models that
account for population heterogeneity.
Acknowledgments
We thank the patients and the staff of dialysis and transplant
units for the contribution of data via their national and regional
registries. We thank the following registries for the contribution of
data: Austrian Dialysis and Transplant Registry (OEDTR; R. Kramar);
Dutch-speaking Belgian Society of Nephrology (NBVN; H. Augustijn
and B. De Moor); French-speaking Belgian Society of Nephrology
(GNFB; J.M. des Grottes); Danish Nephrology Registry (DNS);
Finnish Registry for Kidney Diseases (C. Grönhagen-Riska); The
Epidemiology and Information Network in Nephrology (REIN; M.
Lassalle); Greek Renal Registry (G.A. Ioannidis); Icelandic End-StageRenal Disease Registry; Norwegian Renal Registry (T. Leivestad);
Romanian Renal Registry (RRR; G. Mircescu, L. Garneata, and E.
Podgoreanu); Slovenian RRT Registry (J. Gubensek and M. Arnol);
Swedish Kidney Registry (SNR; K.G. Prütz, L. Bäckman, M. Evans, S.
Schön, M. Stendahl, and B. Rippe); Dutch End-Stage Renal Disease
Registry (RENINE; A. Hoitsma and A. Hemke); UK Renal Registry;
Scottish Renal Registry (SRR); and the regional registries of Anda-
lusia (SICATA; P. Castro de la Nuez), Aragon (J.I. Sanchez Miret and
J.M. Abad Diez), Asturias (R. Alonso de la Torre, J.R. Quirós, and
RERCA Working Group), Basque country (UNIPAR; Á. Magaz, J.
Aranzabal, M. Rodrigo, and I. Moina), Cantabria (M. Arias Rodríguez
and O. García Ruiz), Castile and León (R. González and C. Fernández-
Renedo), Castile-La Mancha (G. Gutiérrez Ávila and I. Moreno Alía),
Catalonia (RMRC; E. Arcos, J. Comas, and J. Tort), Extremadura (J.M.
Ramos Aceitero and M.A. García Bazaga), Galicia (E. Bouzas-Caa-
maño and J. Sánchez-Ibáñez), Community of Madrid (M. Aparicio de
Madre and C. Chamorro Jambrina), and Valencian region (REMRE-
NAL; O. Zurriaga Llorens and M. Ferrer Alamar). We thank the other
ERA-EDTA Registry committee members for their advice in the
J.J.E. Koopman et al. / Annals of Epidemiology 26 (2016) 773e779 779analysis and the drafting of this article. We thank the Registry’s
ofﬁce for the collection and management of data. The ERA-EDTA
Registry is funded by the European Renal AssociationeEuropean
Dialysis and Transplant Association (ERA-EDTA).
This article was written by J.J.E.K., A.K., D.v.H., A.Å., J.B.B., J.B.-P.,
F.C., C.G.C., P.F., J.G.H., Z.A.M., J.M.J.D.M., R.P., R.S., J.P.T., K.J.J., and
H.P. on behalf of the ERA-EDTA Registry which is an ofﬁcial body of
the ERA-EDTA. J.J.E.K. and H.P. conceived and designed the study.
A.K., A.Å., J.-B.B., J.B.-P., F.C., C.G.C., P.F., J.G.H., Z.A.M., J.M.J.D.M., R.P.,
R.S., J.P.T., and K.J.J. collected the data. H.P. constructed the frailty
models. J.J.E.K., A.K., and H.P. analyzed the data. J.J.E.K., A.K., D.v.H.,
and H.P interpreted the results. J.J.E.K. drafted the manuscript. All
authors provided intellectual contributions, read, commented, and
approved the manuscript.Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.annepidem.2016.08.010.
References
[1] Finch CE. Longevity, senescence, and the genome. Chicago: University of
Chicago Press; 1990. p. 12e32.
[2] Arking R. The biology of aging: observations and principles. New York: Oxford
University Press; 2006. p. 26e53.
[3] Vaupel JW. Biodemography of human ageing. Nature
2010;464(7288):536e42.
[4] Driver C. The Gompertz function does not measure ageing. Biogerontology
2001;2(1):61e5.
[5] Rozing MP, Westendorp RGJ. Parallel lines: nothing has changed? Aging Cell
2008;7(6):924e7.
[6] Koopman JJE, Rozing MP, Kramer A, de Jager DJ, Ansell D, De Meester JMJ, et al.
Senescence rates in patients with end-stage renal disease: a critical appraisal
of the Gompertz model. Aging Cell 2011;10(2):233e8.
[7] Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of prema-
ture aging. Am J Kidney Dis 2013;62(2):339e51.
[8] Kooman JP, Kotanko P, Schols AM, Shiels PG, Stenvinkel P. Chronic kidney
disease and premature ageing. Nat Rev Nephrol 2014;10(12):732e42.
[9] Yilmaz MI, Sonmez A, Saglam M, Cayci T, Kilic S, Unal HU, et al. A longitudinal
study of inﬂammation, CKD-mineral bone disorder, and carotid atheroscle-
rosis after renal transplantation. Clin J Am Soc Nephrol 2015;10(3):471e9.
[10] Vaupel JW, Manton KG, Stallard E. The impact of heterogeneity in individual
frailty on the dynamics of mortality. Demography 1979;16(3):439e54.[11] Vaupel JW, Yashin AI. Heterogeneity’s ruses: some surprising effects of
selection on population dynamics. Am Stat 1985;39(3):176e85.
[12] Wienke A. Frailty models in survival analysis. Boca Raton: CRC Press; 2011.
[13] Satayathum S, Pisoni RL, McCullough KP, Merion RM, Wikström B, Levin N,
et al. Kidney transplantation and wait-listing rates from the international
Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int
2005;68(1):330e7.
[14] Hemke AC, Heemskerk MBA, van Diepen M, Weimar W, Dekker FW,
Hoitsma AJ. Survival prognosis after the start of a renal replacement therapy
in the Netherlands: a retrospective cohort study. BMC Nephrol
2013;14:258.
[15] Pippias M, Stel VS, Abad Diez JM, Afentakis N, Herrero-Calvo JA, Arias M, et al.
Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA
Registry Annual Report. Clin Kidney J 2015;8(3):248e61.
[16] Wagner M, Ansell D, Kent DM, Grifﬁth JL, Naimark D, Wanner C, et al. Pre-
dicting mortality in incident dialysis patients: an analysis of the United
Kingdom Renal Registry. Am J Kidney Dis 2011;57(6):894e902.
[17] Kramer A, Stel VS, Caskey FJ, Stengel B, Elliott RF, Covic A, et al. Exploring the
association between macroeconomic indicators and dialysis mortality. Clin J
Am Soc Nephrol 2012;7(10):1655e63.
[18] Rothman KJ. Epidemiology: an introduction. New York: Oxford University
Press; 2002. p. 134.
[19] Vaupel JW, Carey JR, Christensen K, Johnson TE, Yashin AI, Holm NV, et al.
Biodemographic trajectories of longevity. Science 1998;280(5365):855e60.
[20] Yashin AI, Vaupel JW, Iachine IA. A duality in aging: the equivalence of mor-
tality models based on radically different concepts. Mech Ageing Dev
1994;74(1e2):1e14.
[21] Yashin AI, Iachine IA, Begun AS. Mathematical modeling: a review. Math Popul
Stud 2000;8(4):37e41.
[22] Service PM. Heterogeneity in individual mortality risk and its importance for
evolutionary studies of senescence. Am Nat 2000;156(1):1e13.
[23] Pletcher SD, Curtsinger JW. The inﬂuence of environmentally induced het-
erogeneity on age-speciﬁc genetic variance for mortality rates. Genet Res
2000;75(3):321e9.
[24] Barbi E, Caselli G, Vallin J. Trajectories of extreme survival in heterogeneous
populations. Population 2003;58(1):43e65.
[25] Le Cunff Y, Baudisch A, Pakdaman K. How evolving heterogeneity distributions
of resource allocation strategies shape mortality patterns. PLoS Comput Biol
2013;9(1):e1002825.
[26] Koopman JJE, Rozing MP, Kramer A, Abad JM, Finne P, Heaf JG, et al. Calcu-
lating the rate of senescence from mortality data: an analysis of data from the
ERA-EDTA Registry. J Gerontol A Biol Sci Med Sci 2016;71(4):468e74.
[27] Horiuchi S, Wilmoth JR. Deceleration in the age pattern of mortality at older
ages. Demography 1998;35(4):391e412.
[28] Gavrilov LA, Gavrilova NS. Mortality measurement at advanced ages: a study
of the Social Security Administration Death Master File. N Am Actuar J
2011;15(3):432e47.
[29] Vaupel JW, Baudisch A, Dölling M, Roach DA, Gampe J. The case for negative
senescence. Theor Popul Biol 2004;65(4):339e51.
[30] Koopman JJE. Measuring senescence in human populations. Doctoral thesis.
Leiden (The Netherlands): Leiden University; 2015. p. 193e203. Available at:
http://hdl.handle.net/1887/35764 [accessed 22.07.2016].
